Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - IDERA PHARMACEUTICALS, INC. | Financial_Report.xls |
| 10-Q - FORM 10-Q - IDERA PHARMACEUTICALS, INC. | b83415e10vq.htm |
| EX-31.1 - EX-31.1 - IDERA PHARMACEUTICALS, INC. | b83415exv31w1.htm |
| EX-10.2 - EX-10.2 - IDERA PHARMACEUTICALS, INC. | b83415exv10w2.htm |
| EX-10.5 - EX-10.5 - IDERA PHARMACEUTICALS, INC. | b83415exv10w5.htm |
| EX-31.2 - EX-31.2 - IDERA PHARMACEUTICALS, INC. | b83415exv31w2.htm |
| EX-32.2 - EX-32.2 - IDERA PHARMACEUTICALS, INC. | b83415exv32w2.htm |
| EX-32.1 - EX-32.1 - IDERA PHARMACEUTICALS, INC. | b83415exv32w1.htm |
Exhibit 10.1
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
Securities and Exchange Commission. Asterisks denote omissions.
Merck KGaA . Germany . Frankfurter Str. 250 . 64293 Darmstadt
VIA COURIER
Idera Pharmaceuticals, Inc.
|
Date | June 2, 2010 | ||
Steven J. Ritter, Ph.D., J.D.
|
Division/Dept. | Corporate Legal — CL-M | ||
Vice President — Intellectual Property and Contracts
|
Care of | Jens Eckhardt — ns | ||
167 Sidney Street
|
Phone | +49 — 61 51 — 72 23 98 | ||
Cambridge, MA 02139
|
Fax | +49 — 61 51 — 72 23 73 | ||
USA
|
jens.eckhardt@merck.de |
Our license agreement dated December 18, 2007, effective February 4 2008 (the “Agreement”)
Dear Steve,
It is recognized that Idera has met its obligations of delivering [**] Follow-on Compounds in
accordance with Section 3.6 of the Agreement. Merck is actively characterizing these Follow-on
Compounds toward a goal of selecting [**] for possible development. As this characterization is
currently ongoing, Merck requests that Idera allow Merck to extend the period of time for selecting
the Follow-on Compounds such that Merck’s right to make a selection pursuant to Section 3.6 of the
Agreement would expire on [**]. This addition time will enable Merck to further characterize the
Follow-on Compounds and make a more informed decision in the selection process. During this
additional time period, Idera’s role in Merck’s selection process is expected to be passive and no
additional resources are expected to be provided by Idera under the terms of the Agreement.
If you are in agreement with the above please indicate so by returning the attached duplicate of
this letter duly signed.
Very truly yours,
Merck KGaA
|
Agreed: | |||
i.V.
|
i.V. | Idera Pharmaceuticals, Inc. | ||
/s/ Astrid Perschl
|
/s/ Jens Eckhardt
|
/s/ Louis J. Arcudi
|
Merck KGaA · Germany |
||||
Frankfurter Str. 250
|
Partnership limited by shares | Executive Board | ||
64293 Darmstadt
|
Commercial Register AG Darmstadt HRB 6164 | and General Partners: | ||
Phone +49 6151 72-0
|
Registered Office: Darmstadt | |||
Fax +49 6151 72-2000
|
Chairman of the Supervisory Board: | Karl-Ludwig Kley (Chairman), | ||
www.merck.de
|
Wilhelm Simson | Michael Becker, Bernd Reckmann, Elmar Schnee |